{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:52:22Z","timestamp":1756993942109,"version":"3.32.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute promyelocytic leukaemia (APL) with a <jats:italic>STAT5b::RAR\u03b1<\/jats:italic> gene fusion is an extremely rare subtype of APL characterised by resistance to conventional therapies and extremely poor prognosis. This case highlights that whilst APL with variant RAR\u03b1 translocations are rare, they do pose significant challenges both diagnostically and in their clinical management. This case, in the first instance, demonstrates the importance of using a combination of molecular techniques including next generation sequencing (NGS) for diagnosis particularly in morphological and immunophenotypic typical APL which appears negative by confirmatory testing. Secondly, our patient represents, to the best of our knowledge, the first documented example of this rare disease that has been managed with, and shown sensitivity to low-dose cytarabine (LDAC) in combination with venetoclax (Ven). This case demonstrates that although treatment options are extremely limited for patients not eligible for intensive chemotherapy non-intensive options do show increasing promise.<\/jats:p>","DOI":"10.1007\/s11845-024-03751-0","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T03:26:56Z","timestamp":1721446016000},"page":"2875-2881","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of a STAT5b::RAR\u03b1 positive case of APL in a patient not eligible for intensive chemotherapy"],"prefix":"10.1007","volume":"193","author":[{"given":"Jason","family":"Patterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katya","family":"Mokretar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Maurya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Logan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Catherwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Frances","family":"McMullin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,20]]},"reference":[{"key":"3751_CR1","doi-asserted-by":"publisher","unstructured":"Khoury JD, Solary E, Abla O, et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36(7): 1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","DOI":"10.1038\/s41375-022-01613-1"},{"key":"3751_CR2","doi-asserted-by":"publisher","unstructured":"Liquori A, Iba\u00f1ez M, Sargas C, et al (2020) Acute promyelocytic leukemia: a constellation of molecular events around a single PML-RARA fusion gene. Cancers 12(3). https:\/\/doi.org\/10.3390\/cancers12030624","DOI":"10.3390\/cancers12030624"},{"key":"3751_CR3","doi-asserted-by":"publisher","unstructured":"Iyer SG, Elias L, Stanchina M, Watts, J (2023) The treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions. Front Oncol 12. https:\/\/doi.org\/10.3389\/fonc.2022.1062524","DOI":"10.3389\/fonc.2022.1062524"},{"issue":"2","key":"3751_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M and others (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2):111\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa1300874","journal-title":"N Engl J Med"},{"key":"3751_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.leukres.2019.01.004","volume":"78","author":"G Ciangola","year":"2019","unstructured":"Ciangola G, Gurnari C, Paterno G and others (2019) STAT5b-RARa-positive acute myeloid leukemia: diagnostic and therapeutic challenges of a rare AML subtype. Leuk Res 78:21\u201323. https:\/\/doi.org\/10.1016\/j.leukres.2019.01.004","journal-title":"Leuk Res"},{"issue":"2","key":"3751_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/BS9.0000000000000111","volume":"4","author":"G Zhang","year":"2022","unstructured":"Zhang G, Song Y, Wan L and others (2022) Treatment of STAT5b-RARA positive acute promyelocytic leukemia by venetoclax combining with homoharringtonine, cytarabine: a case report and literature review. Blood Sci 4(2):93\u201396. https:\/\/doi.org\/10.1097\/BS9.0000000000000111","journal-title":"Blood Sci"},{"issue":"5","key":"3751_CR7","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.3324\/haematol.2018.205369","volume":"104","author":"L Wen","year":"2019","unstructured":"Wen L, Xu Y, Yao L and others (2019) Clinical and molecular features of acute promyelocytic leukemia with variant retinoid acid receptor fusions. Haematologica 104(5):e195\u2013e199. https:\/\/doi.org\/10.3324\/haematol.2018.205369","journal-title":"Haematologica"},{"issue":"9","key":"3751_CR8","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1093\/hmg\/8.9.1741","volume":"8","author":"C Arnould","year":"1999","unstructured":"Arnould C, Philippe C, Bourdon V and others (1999) The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor in acute promyelocytic-like leukaemia. Hum Mol Genet 8(9):1741\u20131749. https:\/\/doi.org\/10.1093\/hmg\/8.9.1741","journal-title":"Hum Mol Genet"},{"issue":"11","key":"3751_CR9","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1182\/blood.V104.11.3005.3005","volume":"104","author":"RE Gallagher","year":"2004","unstructured":"Gallagher RE, Mak S, Paietta E and others (2004) Identification of a second acute promyelocytic leukemia (apl) patient with the STAT5b-RAR\u03b1 fusion gene among PML-RAR\u03b1-Negative Eastern Cooperative Oncology Group (ECOG) APL Protocol Registrants. Blood 104(11):3005\u20133005. https:\/\/doi.org\/10.1182\/blood.V104.11.3005.3005","journal-title":"Blood"},{"issue":"5","key":"3751_CR10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1600-0609.2008.01042.x","volume":"80","author":"M Kusakabe","year":"2008","unstructured":"Kusakabe M, Suzukawa K, Nanmoku T and others (2008) Detection of the STAT5B\u2013RARA fusion transcript in acute promyelocytic leukemia with the normal chromosome 17 on G-banding. Eur J Haematol 80(5):444\u2013447. https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01042.x","journal-title":"Eur J Haematol"},{"issue":"5","key":"3751_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1600-0609.2009.01324.x","volume":"83","author":"E Iwanaga","year":"2009","unstructured":"Iwanaga E, Nakamura M, Nanri T and others (2009) Acute promyelocytic leukemia harboring a STAT5B-RARA fusion gene and a G596V missense mutation in the STAT5B SH2 domain of the STAT5B-RARA. Eur J Haematol 83(5):499\u2013501. https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01324.x","journal-title":"Eur J Haematol"},{"key":"3751_CR12","doi-asserted-by":"publisher","unstructured":"Cahill TJ, Chowdhury O, Myerson SG, et al (2011) Myocardial infarction with intracardiac thrombosis as the presentation of acute promyelocytic leukemia. Circulation 123(10). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.986208","DOI":"10.1161\/CIRCULATIONAHA.110.986208"},{"issue":"5","key":"3751_CR13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1600-0609.2011.01595.x","volume":"86","author":"C Qiao","year":"2011","unstructured":"Qiao C, Zhang S, Chen L and others (2011) Identification of the STAT5B-RAR\u03b1 fusion transcript in an acute promyelocytic leukemia patient without FLT3, NPM1, c-Kit and C\/EBP\u03b1 mutation. Eur J Haematol 86(5):442\u2013446. https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01595.x","journal-title":"Eur J Haematol"},{"issue":"6","key":"3751_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.cancergen.2012.02.007","volume":"205","author":"H Chen","year":"2012","unstructured":"Chen H, Pan J, Yao L and others (2012) Acute promyelocytic leukemia with a STAT5b-RAR\u03b1 fusion transcript defined by array-CGH, FISH, and RT-PCR. Cancer Genet 205(6):327\u2013331. https:\/\/doi.org\/10.1016\/j.cancergen.2012.02.007","journal-title":"Cancer Genet"},{"issue":"7","key":"3751_CR15","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/leu.2012.371","volume":"27","author":"S Strehl","year":"2013","unstructured":"Strehl S, K\u00f6nig M, Boztug H and others (2013) All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene. Leukemia 27(7):1606\u20131610. https:\/\/doi.org\/10.1038\/leu.2012.371","journal-title":"Leukemia"},{"issue":"1","key":"3751_CR16","doi-asserted-by":"publisher","first-page":"a000307","DOI":"10.1101\/mcs.a000307","volume":"1","author":"MJ Kluk","year":"2015","unstructured":"Kluk MJ, Abo RP, Brown RD and others (2015) Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all- trans retinoic acid resistance identified by a custom next-generation sequencing assay. Mol Case Stud 1(1):a000307. https:\/\/doi.org\/10.1101\/mcs.a000307","journal-title":"Mol Case Stud"},{"issue":"9","key":"3751_CR17","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.3109\/10428194.2015.1007454","volume":"56","author":"Y-Y Wang","year":"2015","unstructured":"Wang Y-Y, Hao J, Liu Z-Y and others (2015) Novel STAT5B\u2013RARA fusion transcript in acute promyelocytic leukemia: identification and treatment response. Leuk Lymphoma 56(9):2731\u20132734. https:\/\/doi.org\/10.3109\/10428194.2015.1007454","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"3751_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3760\/cma.j.issn.0253-2727.2016.01.014","volume":"37","author":"L Liu","year":"2016","unstructured":"Liu L, Chen S, Tan J and others (2016) Acute promyelocytic leukemia with stat5b- RAR\u03b1 fusiongene: a case report and literatures review. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi 37(1):68\u201369. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2016.01.014","journal-title":"Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi"},{"key":"3751_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.bcmd.2017.09.007","volume":"69","author":"C Zhang","year":"2018","unstructured":"Zhang C, Wang Y, Liu B and others (2018) Clinical characteristics of acute promyelocytic leukemia with the STAT5B-RARA fusion gene. Blood Cells Mol Dis 69:71\u201373. https:\/\/doi.org\/10.1016\/j.bcmd.2017.09.007","journal-title":"Blood Cells Mol Dis"},{"issue":"8","key":"3751_CR20","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1080\/10428194.2016.1262952","volume":"58","author":"C Pessina","year":"2017","unstructured":"Pessina C, Basilico C, Genoni A and others (2017) A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion. Leuk Lymphoma 58(8):1977\u20131980. https:\/\/doi.org\/10.1080\/10428194.2016.1262952","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"3751_CR21","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/10428194.2017.1357176","volume":"59","author":"A Wang","year":"2018","unstructured":"Wang A, Cai X, Qiang P, Duan Q (2018) Successful treatment of a patient with acute promyelocytic leukemia with a STAT5B \/ RARA fusion gene using decitabine. Leuk Lymphoma 59(3):763\u2013765. https:\/\/doi.org\/10.1080\/10428194.2017.1357176","journal-title":"Leuk Lymphoma"},{"key":"3751_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cancergen.2019.06.007","volume":"237","author":"JF Peterson","year":"2019","unstructured":"Peterson JF, He RR, Nayer H and others (2019) Characterization of a rarely reported STAT5B\/RARA gene fusion in a young adult with newly diagnosed acute promyelocytic leukemia with resistance to ATRA therapy. Cancer Genet 237:51\u201354. https:\/\/doi.org\/10.1016\/j.cancergen.2019.06.007","journal-title":"Cancer Genet"},{"issue":"43","key":"3751_CR23","doi-asserted-by":"publisher","first-page":"e22923","DOI":"10.1097\/MD.0000000000022923","volume":"99","author":"L Wang","year":"2020","unstructured":"Wang L, Yan X, He J (2020) Does acute promyelocytic leukemia patient with the STAT5B\/RARa fusion gene respond well to decitabine?: A case report and literature review. Medicine 99(43):e22923. https:\/\/doi.org\/10.1097\/MD.0000000000022923","journal-title":"Medicine"},{"issue":"11","key":"3751_CR24","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP and others (2022) International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"issue":"24","key":"3751_CR25","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V and others (2020) Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135(24):2137\u20132145. https:\/\/doi.org\/10.1182\/blood.2020004856","journal-title":"Blood"},{"issue":"8","key":"3751_CR26","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1182\/bloodadvances.2019001278","volume":"4","author":"JE Lancet","year":"2020","unstructured":"Lancet JE, Moseley AB, Coutre SE and others (2020) A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). Blood Adv 4(8):1683\u20131689. https:\/\/doi.org\/10.1182\/bloodadvances.2019001278","journal-title":"Blood Adv"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-024-03751-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-024-03751-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-024-03751-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T23:04:35Z","timestamp":1734995075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-024-03751-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3751"],"URL":"https:\/\/doi.org\/10.1007\/s11845-024-03751-0","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"type":"print","value":"0021-1265"},{"type":"electronic","value":"1863-4362"}],"subject":[],"published":{"date-parts":[[2024,7,20]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}